| Entry |
| ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Name | Bepotastine besylate (USAN); Bepotastine besilate (JP18); Bepreve (TN); Talion (TN) | ||||||||||
| Product | BEPREVE (Bausch & Lomb Incorporated) | ||||||||||
| Generic | BEPOTASTINE BESILATE (Apotex Corp.), BEPOTASTINE BESILATE (Bausch & Lomb Incorporated), BEPOTASTINE BESILATE (Mylan Pharmaceuticals) | ||||||||||
| Formula | C21H25ClN2O3. C6H6O3S | ||||||||||
| Exact mass | 546.1591 | ||||||||||
| Mol weight | 547.0628 | ||||||||||
| Structure |  | ||||||||||
| Class | Anti-allergic agent DG01557 Histamine receptor antagonist DG01482 Histamine receptor H1 antagonist | ||||||||||
| Remark |
| ||||||||||
| Efficacy | Antiallergic, Antipruritic, H1 receptor antagonist | ||||||||||
| Target | HRH1 [HSA:3269] [KO:K04149] | ||||||||||
| Pathway |
| ||||||||||
| Interaction | |||||||||||
| Structure map |
| ||||||||||
| Brite | USP drug classification [BR:br08302] Ophthalmic Agents Ophthalmic Anti-allergy Agents Antihistamine & Mast Cell Stabilizer Bepotastine D01654 Bepotastine besylate (USAN) Therapeutic category of drugs in Japan [BR:br08301] 4 Agents affecting cellular function 44 Allergic agents 449 Miscellaneous 4490 Miscellaneous D01654 Bepotastine besylate (USAN); Bepotastine besilate (JP18) Risk category of Japanese OTC drugs [BR:br08312] Drugs requiring guidance New approved switch OTC drugs Bepotastine D01654 Bepotastine besylate (USAN) Drug groups [BR:br08330] Anti-allergic agent DG01557 Histamine receptor antagonist DG01482 Histamine receptor H1 antagonist DG01327 Bepotastine D01654 Bepotastine besylate Drug classes [BR:br08332] Anti-allergic agent DG01482 Histamine receptor H1 antagonist D01654 Bepotastine besylate Target-based classification of drugs [BR:br08310] G Protein-coupled receptors Rhodopsin family Histamine HRH1 D01654 Bepotastine besylate (USAN) <JP/US> Drugs listed in the Japanese Pharmacopoeia [BR:br08311] Chemicals D01654 Bepotastine besilate D01654 Bepotastine besylate tablets New drug approvals in the USA [br08319.html] New molecular entities and new therapeutic biological products D01654 New drug approvals in Japan [br08318.html] Drugs with new active ingredients D01654 New drug approvals in the USA, Europe and Japan [br08328.html] Approval dates by FDA, EMA and PMDA D01654 Rx-to-OTC switch list in Japan [br08314.html] D01654 Drug groups [BR:br08330] Anti-allergic agent DG01557 Histamine receptor antagonist DG01482 Histamine receptor H1 antagonist DG01327 Bepotastine | ||||||||||
| Other DBs |
| ||||||||||
| KCF data | ATOM 37 1 C8x C 30.3566 -24.1077 2 C8x C 30.3566 -25.5052 3 C8x C 31.5699 -26.2040 4 C8x C 32.7759 -25.5052 5 C8x C 32.7759 -24.1077 6 C8y C 31.5699 -23.4089 7 S4a S 31.5716 -22.0113 8 O1d O 31.6335 -20.6138 9 O1d O 32.9682 -22.0113 10 O1d O 30.1730 -22.0113 11 C1c C 19.5115 -23.1679 12 C8y C 18.2900 -23.8520 13 C8y C 20.7041 -23.8870 14 O2a O 19.5290 -21.7650 15 C8x C 18.2491 -25.2547 16 C8x C 17.0857 -23.1270 17 C1y C 20.8092 -21.0812 18 C8x C 17.0448 -25.9387 19 C8x C 15.8582 -23.8168 20 C8y C 15.8813 -25.2256 21 X Cl 14.6073 -25.9096 22 C1x C 21.9317 -21.7852 23 C1x C 23.1417 -21.1013 24 N1y N 23.1544 -19.7115 25 C1x C 21.9571 -19.0056 26 C1x C 20.7705 -19.7360 27 C1b C 24.3620 -19.0070 28 C1b C 25.5698 -19.6991 29 C1b C 26.7776 -18.9998 30 C6a C 27.9854 -19.6922 31 O6a O 29.1932 -18.9929 32 O6a O 27.9885 -21.0907 33 C8x C 20.7475 -25.3060 34 C8x C 21.8746 -26.0274 35 C8x C 23.1679 -25.3514 36 C8x C 23.1946 -23.9325 37 N5x N 21.9274 -23.2110 BOND 39 1 6 1 1 2 6 7 1 3 7 8 1 4 1 2 2 5 7 9 2 6 2 3 1 7 7 10 2 8 3 4 2 9 4 5 1 10 5 6 2 11 11 12 1 12 11 13 1 13 11 14 1 #Down 14 12 15 2 15 12 16 1 16 14 17 1 17 15 18 1 18 16 19 2 19 18 20 2 20 20 21 1 21 19 20 1 22 17 22 1 23 22 23 1 24 23 24 1 25 24 25 1 26 25 26 1 27 26 17 1 28 24 27 1 29 27 28 1 30 28 29 1 31 29 30 1 32 30 31 1 33 30 32 2 34 13 33 2 35 33 34 1 36 34 35 2 37 35 36 1 38 36 37 2 39 13 37 1 |